| 1 |
32886218 | Improved Erythrocyte Deformability Induced by Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetic Patients. | 2022 Feb |
1 |
| 2 |
34510471 | Metformin and the Risk of Anemia of Advanced Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus. | 2022 Feb |
1 |
| 3 |
35059248 | Dipeptidyl peptidase-4 inhibitor improves glycemic variability in multiple daily insulin-treated type 2 diabetes: a prospective randomized-controlled trial. | 2022 Jan |
1 |
| 4 |
35115253 | Metformin-based single pill drug combinations for type 2 diabetes in primary care England: A time trend analysis. | 2022 Apr |
1 |
| 5 |
35118026 | Correction to: "Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis". | 2022 Jan |
1 |
| 6 |
32745279 | The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands. | 2021 Apr |
1 |
| 7 |
32926865 | Optimization and validation of a fluorogenic dipeptidyl peptidase 4 enzymatic assay in human plasma. | 2021 Jan 1 |
1 |
| 8 |
32994182 | Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling. | 2021 Jan |
4 |
| 9 |
33189895 | Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors? | 2021 Jul |
2 |
| 10 |
33205256 | [Alopecia areata universalis under treatment with sitagliptin : Possible immunological effect of dipeptidyl peptidase-4 inhibitors?] | 2021 Jul |
1 |
| 11 |
33527807 | Clinical Evidence of Evogliptin plus Metformin in Management of Type 2 Diabetes mellitus. | 2021 Feb |
2 |
| 12 |
33669354 | Assessing Scientific Soundness and Translational Value of Animal Studies on DPP4 Inhibitors for Treating Type 2 Diabetes Mellitus. | 2021 Feb 16 |
3 |
| 13 |
33838614 | Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression. | 2021 May-Jun |
1 |
| 14 |
33881795 | Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. | 2021 Aug |
2 |
| 15 |
34057870 | Repurposing metformin for covid-19 complications in patients with type 2 diabetes and insulin resistance. | 2021 Jun |
1 |
| 16 |
34095013 | Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis. | 2021 May |
1 |
| 17 |
34233436 | Urinary exosomal microRNA profiling in type 2 diabetes patients taking dipeptidyl peptidase-4 inhibitor compared with sulfonylurea. | 2021 Sep |
1 |
| 18 |
34287770 | DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020. | 2021 Nov |
1 |
| 19 |
34484112 | Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China. | 2021 |
1 |
| 20 |
34540601 | Association of vitamin B12 deficiency with metformin use in patients with type 2 diabetes treated in the largest tertiary care hospital in Qatar. | 2021 |
1 |
| 21 |
30663560 | Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice. | 2020 |
1 |
| 22 |
31607509 | [Cost-utility study of the combination of metformin with the different glucose-lowering medication classes in adults 80 aged and older]. | 2020 Sep - Oct |
1 |
| 23 |
31789451 | Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes. | 2020 Apr |
1 |
| 24 |
32050809 | Use of oral antidiabetic drugs in Japanese working-age patients with type 2 diabetes mellitus: dosing pattern for metformin initiators. | 2020 May |
2 |
| 25 |
32274915 | Metabolic syndrome in children. | 2020 Aug |
2 |
| 26 |
32878700 | Short-term impact of co-payment level increase on the use of medication and patient-reported outcomes in Finnish patients with type 2 diabetes. | 2020 Dec |
1 |
| 27 |
33116701 | Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study. | 2020 |
2 |
| 28 |
33425803 | Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metformin monotherapy in patients with type 2 diabetes. | 2020 Dec |
2 |
| 29 |
33482956 | Evaluation of Dipeptidyl Peptidase-4 Inhibitors versus Thiazolidinediones or Insulin in Patients with Type 2 Diabetes Uncontrolled with Metformin and a Sulfonylurea in a Real-World Setting. | 2020 Nov |
1 |
| 30 |
30171747 | Which is better, high-dose metformin monotherapy or low-dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low-dose metformin monotherapy? A randomized, cross-over, continuous glucose monitoring-based pilot study. | 2019 May |
1 |
| 31 |
30229901 | Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy. | 2019 Apr 1 |
1 |
| 32 |
30456843 | Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. | 2019 Apr |
10 |
| 33 |
30457671 | A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. | 2019 May |
1 |
| 34 |
30603867 | Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. | 2019 Jun |
2 |
| 35 |
30609212 | Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. | 2019 May |
1 |
| 36 |
30710655 | A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis. | 2019 Mar |
1 |
| 37 |
30904743 | Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. | 2019 May |
1 |
| 38 |
31016151 | Drug Prescription Patterns and Cost Analysis of Diabetes Therapy in India: Audit of an Endocrine Practice. | 2019 Jan-Feb |
1 |
| 39 |
31275243 | DPP-4 Inhibition and the Path to Clinical Proof. | 2019 |
1 |
| 40 |
31275246 | Clinical Use of DPP-4 Inhibitors. | 2019 |
6 |
| 41 |
31330313 | Diabetes drugs in the fight against Alzheimer's disease. | 2019 Sep |
1 |
| 42 |
31559762 | HbA1C in Management of Type II Diabetes Mellitus: A Cross-sectional Survey of Indian Physicians. | 2019 Jul |
1 |
| 43 |
31695754 | Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database. | 2019 |
1 |
| 44 |
28418203 | Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting. | 2018 Jan |
1 |
| 45 |
28704854 | Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors. | 2018 May |
1 |
| 46 |
29138876 | Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. | 2018 Mar |
1 |
| 47 |
29144805 | DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY. | 2018 Jan |
2 |
| 48 |
29170542 | Diabetes: Metformin - a cardiovascular moderator of DPP4 inhibitors? | 2018 Jan |
1 |
| 49 |
29285650 | Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells. | 2018 Feb |
1 |
| 50 |
29391064 | Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. | 2018 Feb 1 |
1 |